Current status of poly (ADP-ribose) polymerase inhibitors and future directions
A Ohmoto, S Yachida - OncoTargets and therapy, 2017 - Taylor & Francis
Inhibitors of poly(ADP-ribose) polymerases (PARPs), which play a key role in DNA damage/repair
pathways, have been developed as antitumor agents based on the concept of …
pathways, have been developed as antitumor agents based on the concept of …
[HTML][HTML] Germline mutations in Japanese familial pancreatic cancer patients
…, S Yachida, K Shimizu, J Furuse, E Kubo, A Ohmoto… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Clinicopathologic and genetic features of familial pancreatic cancer (FPC) in Asian countries
remain largely unknown. The main purpose of this study was to determine the prevalence …
remain largely unknown. The main purpose of this study was to determine the prevalence …
[HTML][HTML] Pancreatic neuroendocrine neoplasms: basic biology, current treatment strategies and prospects for the future
A Ohmoto, H Rokutan, S Yachida - International journal of molecular …, 2017 - mdpi.com
… Akihiro Ohmoto … Akihiro Ohmoto contributed to the concept of the work; Akihiro Ohmoto,
Hirofumi Rokutan and Shinichi Yachida wrote and revised the manuscript. …
Hirofumi Rokutan and Shinichi Yachida wrote and revised the manuscript. …
[HTML][HTML] Genomic features and clinical management of patients with hereditary pancreatic cancer syndromes and familial pancreatic cancer
A Ohmoto, S Yachida, C Morizane - International journal of molecular …, 2019 - mdpi.com
Pancreatic cancer (PC) is one of the most devastating malignancies; it has a 5-year survival
rate of only 9%, and novel treatment strategies are urgently needed. While most PC cases …
rate of only 9%, and novel treatment strategies are urgently needed. While most PC cases …
Cardiac complications associated with hematopoietic stem-cell transplantation
A Ohmoto, S Fuji - Bone Marrow Transplantation, 2021 - nature.com
Advances in chemotherapy and supportive therapy have resulted in improved clinical
outcomes in patients with hematological malignancies undergoing hematopoietic stem-cell …
outcomes in patients with hematological malignancies undergoing hematopoietic stem-cell …
[HTML][HTML] Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
A Ohmoto, Y Sato, R Asaka, N Fukuda, X Wang… - Modern Pathology, 2021 - Elsevier
Neuroendocrine carcinoma (NEC) of the head and neck is a rare type of malignancy,
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …
Sequential analysis of neutrophil-to-lymphocyte ratio for differentiated thyroid cancer patients treated with lenvatinib
N Fukuda, X Wang, A Ohmoto, T Urasaki, Y Sato… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…
Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer
…, N Fukuda, YU Fujiwara, X Wang, T Urasaki, A Ohmoto… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC),
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
First‐in‐human study of E7130 (a tumor microenvironment‐ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose …
…, Y Kuboki, K Harano, M Ono, T Urasaki, A Ohmoto… - Cancer, 2023 - Wiley Online Library
Background E7130 is a novel anticancer agent created from a total synthetic study of
norhalichondrin B. The authors report the E7130 dose‐escalation part of a first‐in‐human study of …
norhalichondrin B. The authors report the E7130 dose‐escalation part of a first‐in‐human study of …
Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib
N Fukuda, K Toda, YU Fujiwara, X Wang, A Ohmoto… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …